Home > Healthcare & Medical Devices > Outpatient Oncology Infusion Market

Outpatient Oncology Infusion Market Size, Share and Industry Analysis Report by Product (Infusion Pumps, Intravenous Sets, IV Cannulas, Needleless Connectors), Application (Lung Cancer, Liver Cancer, Breast Cancer, Prostate Cancer), By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy) and Mode (Intramuscular (IM), Intravenous (IV), Subcutaneous), Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022– 2030

  • Report ID: GMI5268
  • Published Date: May 2022
  • Report Format: PDF

Industry Overview

Outpatient Oncology Infusion Market size surpassed USD 63.6 billion in 2021 and is expected to witness 11% CAGR from 2022 to 2030 owing to the rapid increase in product demand and the increase in medical costs around the world. Surging technological advancements in infusion pumps along with growing safety concern associated with the cancer therapy will accelerate the business growth.
 

outpatient oncology infusion market outlook

Get more details on this report - Request Free Sample PDF
 

In addition, continuous improvement in cancer infusion therapy, availability of skilled nursing staff, professional training, and transparency regarding quality of care are expected to drive industry growth. In addition, rapid technological advances in intravenous devices, along with the government's favorable policies for the elderly, have boosted the demand for outpatient oncology infusion therapy devices.
 

The COVID-19 pandemic had a moderate impact on the outpatient oncology infusion market. In the midst of a pandemic, identifying new cancer cases around the world is declining and lagging. In addition, cancer patients have reported delays in cancer treatment, including clinic follow-up appointments and cancer therapies, such as infusion therapies, surgical tumor removal and radiation therapy. However, as the restrictions got removed in 2021, treatment for breast, urinary and gynecologic tumors increased (between 3% and 73%).
 

The outpatient oncology infusion centers offer a variety of treatments such as chemotherapy, blood transfusions, platelet transfusions, IV antibiotics, and hydration and electrolyte replacement. It also provides long-term and short infusion therapy to patients in an appropriate manner. Outpatient oncology infusion therapy delivers medications intravenously.
 

Rising prevalence of cancer will boost the industry growth over the analysis period

The rising prevalence of various types of cancer across the globe are expected to spur market growth. For instance, according to the World Cancer Report, cancer prevalence is expected to rise by approximately 50% by 2020, with over 15 million new cancer cases. Moreover, increasing tobacco and alcohol consumption has increased the global cancer burden. Thus, the above-mentioned factors are projected to expedite the outpatient oncology infusion market growth in the near future.
 

For instance, according to the National Cancer Registry of India (NCRI), in 2020, approximately 27 percent of cancer cases found in India due to tobacco consumption. As a result of the rising oncology burden, the adoption rate of oncology infusion therapy and subsequent treatment will accelerate, boosting market growth.
 

Furthermore, the estimated national cancer treatment cost in the U.S. in 2018 was USD 150.8 billion. Over the next few years, costs can increase as the population ages and more people develop cancer. Costs can also increase as new and often more expensive treatments are introduced as standard of care.
 

Increasing demand for infusion pumps will augment the outpatient oncology infusion business growth

outpatient oncology infusion market by product

 

Get more details on this report - Request Free Sample PDF
 

Based on product, the infusion pump segment accounted for around 50% market share in 2021 owing to the growing cancers instances across the globe coupled with the growing use of infusion pumps for cancer therapy. For instance, as per World Health Organization (WHO), in 2018, cancer was estimated to be the second most prominent cause of death globally and is responsible for about 9.6 million deaths. Furthermore, cancer patients require continuous delivery of chemotherapy, which can be accomplished with the use of infusion pumps.
 

Infusion pumps are used to deliver fluids precisely and consistently such as medicines, antibiotics, and nutrients in a patient's body. Also, infusion pumps such as ambulatory chemotherapy pumps, and implantable pumps, are useful for managing cancer in hospitals, outpatient care centers, and home care settings. Such benefits associated with this product will spur the segmental as well as outpatient oncology infusion market growth over the forecast period.
 

Increasing lung cancer cases will foster the market growth

outpatient oncology infusion market by application

Get more details on this report - Request Free Sample PDF
 

By application, the lung cancer segment accounted for around USD 6.7 billion market size in 2021. The factors such as rising occurrences of lung cancer and rising level of geriatric population along with changing lifestyles with high smoking habits, further results in a large pool of carcinoma lung population that fosters demand for outpatient oncology infusion therapy. Thus, augmenting market growth.
 

For instance, according to the American Cancer Society 2022, lung cancer is the leading cause of death in both men and women, accounting for over 25% of all cancer-related deaths.
 

Moreover, the surging introduction of targeted therapies for the treatment of lung cancer will propel the outpatient oncology infusion market during the analysis timeframe. For instance, in September 2018, Pfizer Inc., received the U.S. FDA approval for VIZIMPRO (dacomitinib) for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer.
 

Surging demand for chemotherapy will augment the outpatient oncology infusion business growth over the projected timeline

Based on therapy, The chemotherapy segment accounted for over 17% market share in 2021 and is estimated to expand at a substantial pace over the analysis timeframe due to the advantages offered by the infusion treatment in chemotherapy coupled with the increasing demand for outpatient oncology infusion chemotherapy for the treatment of cancer diseases. Doctors highly recommend infusion therapy for cancer patients because it permits specifically designed medicines to permeate the body that inhibit cellular mitosis. As per the recent research, the potential advantages of treating cancer at the outpatient center through infusion therapy include relieving distress from symptoms, reducing the risk of complications, and cost-effective than hospital-based care.
 

Outpatient infusion intravenous chemotherapy allows patients to better manage their symptoms and adherence to chemotherapy schedules. Moreover, novel chemotherapy infusion systems deliver improved quality of life and allow precise monitoring of the patient through connected devices. Hence, the several benefits provided by chemotherapy in cancer patients have stimulated outpatient oncology infusion industry growth.
 

Intravenous route of administration will augment the business growth

Based on mode, The intravenous (IV) segment accounted for around 31% of market share in 2021 owing to the benefits provided by intravenous infusion therapy treatment. This intravenous infusion of antibiotic drugs is highly used to treat disorders that do not respond to oral therapeutics, thereby significantly driving the demand for outpatient oncology infusion and will spur the overall market expansion.
 

Also, intravenous is one of the common routes of administration for chemotherapy and immunotherapy process. Furthermore, intravenous route delivers medications quickly and replace fluid throughout the body as they are introduced directly into the circulatory system. For this reason, the IV route is usually recommended in emergencies or when prompt action is desired.
 

Surging awareness in the North America region to reduce the cancer burden is predicted to stimulate the regional market growth

North America Outpatient Oncology Infusion Market, By Country

Get more details on this report - Request Free Sample PDF
 

North America outpatient oncology infusion industry accounted for a significant share in 2021 and is anticipated to expand at a notable pace to reach around USD 68 billion by 2030 owing to various factors such as the favorable government initiatives, increasing cancer patient and rising geriatric population among others.
 

For instance, as per the Population Reference Bureau, the number of Americans aged 65 and more is expected to double by 2060, from 52 million in 2018. The rising prevalence of chronic diseases such as cancer is also aided market expansion. For instance, according to the National Cancer Institute, in 2020, in the U.S. around 1,806,590 cancer cases were identified.
 

Besides, increasing product approval in the North America also contributes to regional market growth. For instance, in May 2021, Amgen received U.S. Food and Drug Administration (FDA) approval for LUMAKRAS (sotorasib) for the treatment of adult patients with KRAS G12C- metastatic non-small cell lung cancer (NSCLC). This approval aided the company to drive product sales and bolster its industrial position in North America outpatient oncology infusion industry.
 

Innovative strategies by key market players will upsurge growth opportunities in outpatient oncology infusion market

Some of the key market players operating in the outpatient oncology infusion industry include B. Braun Melsungen AG, Baxter, Becton, Dickinson, and Company, Fresenius Kabi, ICU Medical, Inc., IRadimed Corporation, Nipro Corporation, Terumo Corporation, Smiths Medical, Medtronic PLC, Roche Diagnostics, and Teleflex, Inc., among others.  These market players are employing a variety of development strategies, including continual innovation and technological advancements, in order to maintain market rivalry in the outpatient oncology infusion market.
 

Some of the recent industry developments:

  • In January 2022, ICU Medical acquired Smiths Medical from Smiths Group plc. Smiths Medical segment included syringe and ambulatory infusion devices, vascular access, and vital care products. This focused mainly on providing quality, innovative and value-added services. Such strategies will help company in boosting its market position.
     
  • In March 2020, Fresenius Kabi received U.S. Food and Drug Administration approval for its wireless Agilia Connect Infusion System that includes Agilia Volumetric Pump and Agilia Syringe Pump with Vigilant Software Suite-Vigilant master med technology. This enables distribution of drug libraries, warehousing of infusion data for reporting and analysis and calibration of devices and maintaining wireless system. This is projected to boost company presence and outpatient oncology infusion market growth.
     

The outpatient oncology infusion market report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2022 to 2030, for the following segments:

By Product

  • Infusion Pumps
  • Intravenous Sets
  • IV Cannulas
  • Needleless Connectors

By Application

  • Lung Cancer
  • Liver Cancer
  • Breast Cancer
  • Prostate Cancer
  • Others

By Therapy

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hormonal Therapy

By Mode

  • Intramuscular (IM)
  • Intravenous (IV)
  • Subcutaneous
  • Others

The above information is provided for the following regions and countries:

By Region

  • North America 
    • U.S.
    • Canada
  • Europe 
    • Germany
    • UK
    • France
    • Spain
    • Italy
  • Asia Pacific 
    • Japan
    • China
    • India
    • Australia
  • Latin America 
    • Brazil
    • Mexico
  • Middle East & Africa 
    • South Africa
    • Saudi Arabia
    • UAE

 

Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

The global outpatient oncology infusion industry is slated to surpass USD and 162.4 billion by 2030 and is pegged to strike an 11% CAGR from 2022 to 2030 due to the increasing medical costs and the rapidly growing technological advancements.

The infusion pump product segment accounted for more than 50% of the outpatient oncology infusion industry share in 2021 and will witness expansion on account of the rise in the number of cancer cases across the globe.

The outpatient oncology infusion industry share from lung cancer applications is likely to record close to USD 6.7 billion in 2021 due to the increasing number of lung cancer and the expanding geriatric population.

The chemotherapy therapy segment held over 17% of the outpatient oncology infusion market share in 2021 and will expand with the rising need in the treatment of cancer diseases.

The outpatient oncology infusion market in North America is likely to surpass USD 68 billion by 2030 driven by the presence of favorable government initiatives, increasing cancer patient rate, and the proliferating geriatric population.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies
Immediate Delivery Available

Premium Report Details

  • Base Year: 2021
  • Companies covered: 12
  • Tables & Figures: 129
  • Countries covered: 16
  • Pages: 140

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount